- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
On Thursday, October 2, 2008, Dr. Tamarkin will be a featured speaker from 10:30-12:30 in the medicine and biology track at NanoTx08. His speech will focus on the recent Phase I CYT-6091 cancer patient trial in which the Company's gold nanomedicine was used to deliver a potent, but toxic, anti-cancer therapeutic to solid tumors. Such tumor targeting is best accomplished by avoiding uptake by the immune system and by limiting the biodistribution of the drug to the tumor. CYT-6091 accomplishes this by binding the potent, but toxic molecule TNF to the surface of PEGylated colloidal gold nanoparticles. TNF's toxicity is so severe that its clinical use is limited to isolated limb perfusion (ILP), where 1 mg of TNF followed by doxorubicin results in a 60-85% local response rate. In the completed CYT-6091 Phase I dose escalation clinical trial a similar dose of TNF was injected systemically. The treatment was well-tolerated, showing no dose limiting toxicity, and patient biopsies taken 24-hours after treatment showed gold nanoparticles in patient tumors. Multiple Phase II combination trials are planned.
About CytImmune Sciences, Inc.
CytImmune Sciences is a clinical stage nanomedicine company with a core focus on the discovery, development and commercialization of multifunctional, tumor-targeted therapies. Based on an R&D strategy which harnesses the unique properties of gold nanoparticles, cytotoxic agents, and biology of tumors, the Company is developing a pipeline of proprietary drug candidates binding potent anti-cancer agents -- whose toxicity profiles currently prevent or severely limit clinical use -- to its patented colloidal gold tumor-targeting nanotechnology.
Leveraging its expertise in colloidal gold-based nanomedicines, CytImmune has also developed a patented, semi-synthetic in vitro immune system capable of producing fully-human monoclonal antibody (mAb) therapeutics. The Company’s ability to produce fully human mAbs provides an additional pathway to develop proprietary anti-cancer therapeutics using its platform technology to create a separate class of nanomedicines.
For more information, please click here
9640 Medical Center Drive
Rockville, MD 20850
Fax: (301) 315-2438
Copyright © CytImmune Sciences, Inc.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Researchers create a first frequency comb of time-bin entangled qubits: Discovery is a significant step toward multi-channel quantum communication and higher capacity quantum computers April 28th, 2016
Introducing the RE標ORK Bio-inspired Robotics Summit in Berlin April 27th, 2016